NYSE:HAE Haemonetics (HAE) Stock Price, News & Analysis $104.77 +0.40 (+0.38%) Closing price 10/2/2026 03:59 PM EasternExtended Trading$104.46 -0.32 (-0.30%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Haemonetics Stock (NYSE:HAE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Haemonetics alerts:Sign Up Key Stats Today's Range$103.61▼$105.7050-Day Range$80.07▼$108.9452-Week Range$48.17▼$110.45Volume328,573 shsAverage Volume536,211 shsMarket Capitalization$4.77 billionP/E Ratio51.36Dividend YieldN/APrice Target$99.78Consensus RatingModerate Buy Company Overview Haemonetics Corporation (NYSE: HAE) is a medical technology company that develops and supplies products and software for blood management. Its solutions are used to collect, process, manage and analyze blood and blood components, helping healthcare providers and blood and plasma collection organizations improve the availability, safety and efficiency of transfusion-related care. The company’s portfolio includes plasma and blood component collection systems, disposable collection and processing kits, surgical blood recovery and autotransfusion systems, and technologies used to assess coagulation and hemostasis. Haemonetics also provides software and related services that support blood-center operations, hospital transfusion management and inventory workflows. Its products include the NexSys and PCS plasma collection systems, Cell Saver blood recovery systems and TEG hemostasis analyzers. Founded in 1971, Haemonetics serves hospitals, blood centers, plasma collectors and other healthcare organizations internationally. The company operates across North America, Europe and other global markets through direct operations and distribution relationships. Its corporate headquarters are in Boston, Massachusetts.AI Generated. May Contain Errors. Read More Haemonetics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks34th Percentile Overall ScoreHAE MarketRank™: Haemonetics scored higher than 34% of companies evaluated by MarketBeat, and ranked 731st out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingHaemonetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 1 strong buy rating, 6 buy ratings, 4 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for Haemonetics is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageHaemonetics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Haemonetics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth8.32% Earnings GrowthEarnings for Haemonetics are expected to grow by 8.32% in the coming year, from $5.29 to $5.73 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Haemonetics is 51.36, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 44.65.Price to Earnings Ratio vs. SectorThe P/E ratio of Haemonetics is 51.36, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.71.Price to Earnings Growth RatioHaemonetics has a PEG Ratio of 2.10. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioHaemonetics has a P/B Ratio of 6.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Haemonetics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.69% of the float of Haemonetics has been sold short.Short Interest Ratio / Days to CoverHaemonetics has a short interest ratio ("days to cover") of 5.69.Change versus previous monthShort interest in Haemonetics has recently increased by 19.60%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHaemonetics does not currently pay a dividend.Dividend GrowthHaemonetics does not have a long track record of dividend growth. News and Social Media2.0 / 5News Sentiment0.27 News SentimentHaemonetics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Haemonetics this week, compared to 5 articles on an average week.Search InterestOnly 2 people have searched for HAE on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Haemonetics insiders have not sold or bought any company stock.Percentage Held by Insiders2.07% of the stock of Haemonetics is held by insiders.Percentage Held by Institutions99.67% of the stock of Haemonetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Haemonetics' insider trading history. Receive HAE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Haemonetics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HAE Stock News HeadlinesHaemonetics (HAE) Gets a Buy from Barrington4 hours ago | theglobeandmail.comReviewing Femasys (NASDAQ:FEMY) and Haemonetics (NYSE:HAE)October 2 at 5:15 AM | americanbankingnews.com"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you make with it. Using the 4% rule as a benchmark, that balance could translate to about $100,000 in year one, adjusted upward for inflation each year after. But the 4% rule has potential downsides and may not fit every portfolio. A financial advisor can help size and structure a retirement budget around your income sources, taxes, and goals. SmartAsset's free quiz matches nearly 50,000 people each month with vetted fiduciary advisors.October 4 at 1:00 AM | SmartAsset (Ad)Reviewing Intuitive Surgical (NASDAQ:ISRG) & Haemonetics (NYSE:HAE)October 2 at 4:29 AM | americanbankingnews.comHaemonetics Corporation (NYSE:HAE) Stock Has Average Target Price of $99.78October 2 at 2:15 AM | americanbankingnews.comHaemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026September 30, 2026 | prnewswire.comHaemonetics (HAE) Could Be 66% Undervalued After Margin Expansion FocusSeptember 22, 2026 | finance.yahoo.comCitigroup upgrades Haemonetics to buy from neutralSeptember 18, 2026 | msn.comSee More Headlines HAE Stock Analysis - Frequently Asked Questions How have HAE shares performed this year? Haemonetics' stock was trading at $80.14 at the beginning of the year. Since then, HAE stock has increased by 30.7% and is now trading at $104.7710. How were Haemonetics' earnings last quarter? Haemonetics Corporation (NYSE:HAE) announced its quarterly earnings results on Thursday, August, 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.06. The firm's quarterly revenue was up 5.5% on a year-over-year basis. Read the conference call transcript. Who are Haemonetics' major shareholders? Top institutional investors of Haemonetics include Confluence Investment Management LLC (0.03%). Insiders that own company stock include Michelle L Basil, Anila Lingamneni, Josep Llorens and Stewart W Strong. View institutional ownership trends. How do I buy shares of Haemonetics? Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Haemonetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Haemonetics investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH), The RMR Group (RMR) and AUO (AUOTY). Company Calendar Last Earnings8/06/2026Today10/04/2026Next Earnings (Estimated)11/05/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 HAE's financial health is in the Green zone, according to TradeSmith. HAE has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNYSE:HAE CIK313143 Webwww.haemonetics.com Phone(781) 848-7100Fax781-848-5106Employees3,009Year Founded1971Price Target and Rating Average Price Target for Haemonetics$99.78 High Price Target$125.00 Low Price Target$78.00 Potential Upside/Downside-4.8%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)$2.04 Trailing P/E Ratio51.36 Forward P/E Ratio19.81 P/E Growth2.1Net Income$97.31 million Net Margins7.12% Pretax Margin9.65% Return on Equity27.55% Return on Assets9.65% Debt Debt-to-Equity Ratio1.40 Current Ratio3.08 Quick Ratio1.91 Sales & Book Value Annual Sales$1.33 billion Price / Sales3.57 Cash Flow$7.59 per share Price / Cash Flow13.81 Book Value$17.14 per share Price / Book6.11Miscellaneous Outstanding Shares45,500,000Free Float44,555,000Market Cap$4.77 billion OptionableOptionable Beta0.61 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NYSE:HAE) was last updated on 10/4/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Haemonetics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Haemonetics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
